[ad_1]
New York, December 13, 2021 (Global News Agency)-Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating against Revance Therapeutics, Inc. (“Revance Therapeutics” or “Company”) (NASDAQ: G) Potential claims:RVNC) And remind investors to seek the lead plaintiff’s role in the federal securities class action against the company within the deadline of February 8, 2022.
If you suffered a loss of more than $100,000 from investing in Revance Therapeutics stocks or options between November 25, 2019 and October 11, 2021 And want to discuss your legal rights, please call Faruqi & Faruqi partners Direct Josh Wilson exist 877-247-4292 or 212-983-9330 (extension 1310). You can also click here for more information: www.faruqilaw.com/RVNC.
You do not have to bear any fees or obligations.
Faruqi & Faruqi is a leading minority and female-owned national securities law firm with offices in New York, Pennsylvania, California, and Georgia.
As detailed below, the focus of the lawsuit is whether the company and its executives violated the Federal Securities Law by making false and/or misleading statements and/or failing to disclose the following: (1) Quality control defects exist in…
The full story can be found on Benzinga.com
[ad_2]
Source link
